Oncolytics Biotech Inc ONCY

ONCY January 2024 slide deck - over 120 panc pts studied

[Noteable]

Positive Data from over 120 pancreatic cancer patients in the GOBLET and REO-017 open label trials showed meaningful improvements in survival

ONCY's adaptive study involving  more than 120 pancreatic patients is more than sufficient when applying for an FDA's Accelerated Approval 

Plans are underway to define the Phase 3, adaptive-design protocol in H1 2024.

Guidance on breast cancer registration plan expected in H1 2024

Pancreatic Cancer Adaptive Phase 3 intended to begin in mid-2024

Collaborations with Roche, Merck and others, Fast Track Designations, and cash of $40 million (a/o Q3 '23) , providing a runway of over 12 months

https://oncolyticsbiotech.com/wp-content/uploads/2024/01/Oncolytics.Deck_.January.pdf

[Noteable]

REO-17 involving pelareorep + gemcitabine demonstrated : -- More Than Doubling in One-Year Survival and Nearly Five-Fold Increase in Two-Year Survival as Compared to Historical Controls--  A survival analysis for 33 patients showing a median progression free survival (PFS) of four months and median overall survival (OS) of 10.2 months; Data showing one- and two-year survival

[Noteable]

The metastatic pancreatic cancer arm of the Goblet Phase 2 study involving pelareorep + atezolizumsb + n-paclitaxel resulted in :  an overall response rate  (ORR) of 62% (54% confirmed by two or more scans), a Disease Control Rate (DCR) of 85%, 7.2 months of median progression-free survival (mPFS), interim median overall survival (imOS) of 10.6 months, and expansion of

[Noteable]

The results of over 120 pancreatic patients in ONCY's adaprive pancreatic studies (REO-17 and Goblet) are enough for an Accelerated Approval, followed by a confirmatory Phase 3 study by mid this year.

[Quentin30]

Oh well I'm glad that you know the full results of the trial already Noteable... phew.. Hmmm, why is it that ONCY doesn't state in their plush new slide deck that they are aiming for accelerated approval..? Do you think they are deliberately holding this back so that the stock price can tank even more..?  It's great that we have you here to tell us all how ONCY is worth 10

[Noteable]

Should read: " ...120 pancreatic patients in ONCY's adaptive pancreatic studies (REO-17 and Goblet)..."  Merck's (MSD) Keynote-001. multicohort, open-label, phase 1 study of pembrolizumab, was an adaptive study that led to accelerated approvals in 2 indications. In March 2023 - The US Food and Drug Administration (FDA) issued draft guidance on the design of

[Noteable]

those manipulative trader/brokers, the likes of Quentin30 and his crew on this message board, through the apparent likes of CIBC World Markets and Canacccord, as examples, have been involved in manipulating the price of this stock at a "full bore" pace, unsuccesffuly trying to acquire a controlling interest in the stock.  

[13X2413]

I appreciate your efforts in trying to prop this baby up as much as possible. It's not working. The people that follow this board don't have enough pull to affect the share price either way. We need some kind of positive action from company. They don't seem to have concerns about the price tanking at a steady pace. Pretty disappointing. 

[Azzak34]

It's my absolute favorite when you idiots speak for dozens of others without being appointed to.  Just you speak for yourself and let's others do the same. This will pop when it's good and ready. Don't believe that then sell up amd leave me your contact info to send my Vegas pics. 

[Lesalpes29]

We need a positive post... good news are coming next week for sure. GL

[Noteable]

those manipulative trader/brokers, the likes of Quentin30, lonc17, O'henry, numbersxnumbers and crew on this and other message boards, through the apparent likes of CIBC World Markets and Canacccord, as examples, have been involved in manipulating the price of this stock at a "full bore" pace, unsuccesffuly trying to acquire a controlling interest in the stock.

[13X2413]

Another fine week in the books. Regarding traders wanting controlling interest in this.....I hope that was a joke. Who in the right mind would want any interest in this pig? I'm stuck because I didn't have the nerve to take a loss and fly the coop. I got sucked in by the pump job, hoping for that elusive miracle. I hate to admit it. 

[Azzak34]

Good. I sure hope that sting will learn ya a lesson.  Or, or... you ain't got share 1 and having another lil dig. Gosh I sure hope it's the former. 

[Quentin30]

sadly that's how I got suckered into this dog of stock aswell 13X2413... I naively believed the pumper crowd.  But after 10 years of hearing the same mantra, pivotal results in the next 12-18 months...  one statys to grow weary... As for being part of an orchestrated cabal looking to buy ONCY on the cheap... yah right - that must be true, because ONCY is valued at under 100 million

[Noteable]

Again, those manipulative trader/brokers, the likes of Quentin30, lonc17, O'henry, numbersxnumbers and crew on this and other message boards, through the apparent likes of CIBC World Markets and Canacccord, as examples, have been involved in manipulating the price of this stock at a "full bore" pace, unsuccesffuly trying to acquire a controlling interest in the stock

[13X2413]

Note, No offence, but it looks like you're in scramble mode. If all else fails, take the stock manipulation route. 

[Quentin30]

what a pity that Pela doesn't cure delusions...   You are so wrong Noteable its almost beyond ridiculous... but the shameful thing is you keep stating that the ones challenging the pumpers on this bb are part of some scheme to aquire ONCY on the cheap... well, If ONCY were to release data that unassailably demonstrates with statisitical significance that Pela in combo is effective

[Noteable]

And again, ... those manipulative trader/brokers, the likes of Quentin30, lonc17, O'henry, numbersxnumbers and crew on this and other message boards, through the apparent likes of CIBC World Markets and Canacccord, as examples, have been involved in manipulating the price of this stock at a "full bore" pace, unsuccesffuly trying to acquire a controlling interest in the stock

[Noteable]

Again ... those manipulative trader/brokers, the likes of Quentin30, lonc17, O'henry, numbersxnumbers and crew on this and other message boards, through the apparent likes of CIBC World Markets and Canacccord, as examples, have been involved in manipulating the price of this stock at a "full bore" pace, unsuccesffuly trying to acquire a controlling interest in the stock.

[Noteable]

Add Lesalpes29 to the list of those manipulative trader/brokers who are involved in manipulating the price of this stock at a "full bore" pace, unsuccesffuly trying to acquire a controlling interest in the stock.

[13X2413]

The only successful people are the shorts. No manipulation, just a good old fashioned pump job coming to a close.  Don't get me wrong, I'm not enjoying seeing my money going down the tubes. You win some and you lose some. This one hurt. 

[CMHarring218431]

Well, don't add me to the list, but could a lot of the recent decline be attributed to leaks that informed the bad guys ONC was going it alone? ANson must have been undoubtedly in the know. Can we assume Roche is not interested in partnering and/or a buyout, at this time. Or, is it a concerted effort on the part of Roche and ONC to let the CRO run this P3 clinical trial at less expense i.e

[canadafan]

I don't mind repeating the answers to reasonable questions. regarding Onc doing a phase 3 on their own? It always ( since incorporation & original mission statement), to get Pela to a stage of approval, then partner &/ or be sold. Partnering has always been their public discussion. Up to & including present day on- line corporate update. ONC has $$$ funding to operate 12

[Noteable]

Again ... those manipulative trader/brokers, the likes of Quentin30, lonc17, O'henry, numbersxnumbers, Lesalpes29, Venture009, CMHarring218431, and crew on this and other message boards, through the apparent likes of CIBC World Markets and Canacccord, as examples, have been involved in manipulating the price of this stock at a "full bore" pace, unsuccesffuly trying to acquire a

[CMHarring218431]

Noteable, made the list ...really? You remind me of Bobby Knight who actually recruited while in High School to go to West Point. Yes, I am too old to be playing games. What is your problem with tossing around possible and unknown scenarios. Well, its not about me. I'm out of here

[Noteable]

CMHarring218431 posting FUD is the epitomy of  "playing games".

[CMHarring218431]

I don't want to get into a pissing contest but you are just wrong and the epitome (no y) of someone who has to be correct all the time especially if it does not further their agenda. So, back off. You are wrong

[Noteable]

  CMHarring218431 ... I post facts. Deal with it. CMHarring218431

[venture009]

Noteable this is suppose to be a discussion site. Some of us have legitimate concerns when the sp continues to decline and ONC's available cash is now below 12 months and they seem to be sending mixed signals, which the investment community punishes the sp. People that have an investment have as much right to voice their concern as your continually pushing hypothetical scenarios and you have

[Noteable]

Heeere's Johnnieee  ..again ! ... those manipulative trader/brokers, the likes of Quentin30, lonc17, O'henry, numbersxnumbers, Lesalpes29, Venture009, CMHarring218431, and crew on this and other message boards, through the apparent likes of CIBC World Markets and Canacccord, as examples, have been involved in manipulating the price of this stock at a "full bore" pace

[Noteable]

Interesting ... all those manipulative trader/brokers, the likes of Quentin30, lonc17, O'henry, numbersxnumbers, Lesalpes29, Venture009, CMHarring218431, and crew on this and other message boards, through the apparent likes of CIBC World Markets and Canacccord, as examples, have at least 311+ likes on this message board that appear within minutes of their posting.

[Noteable]

Should read :   ...Interesting ... all those manipulative trader/brokers, the likes of Quentin30, lonc17, O'henry, numbersxnumbers, Lesalpes29, Venture009, CMHarring218431, and crew on this and other message boards, through the apparent likes of CIBC World Markets and Canacccord, as examples, have at least 311+ "views" on this message board that appear within minutes

[CMHarring218431]

Oh boy....you went and added these up. Man, you got issues. Yes, you post a lot of facts none of which guarantee anything. Your recent redundancy concentrating on naming names and reposting of successful Pela achievements and big Pharma buyouts makes you look desperate. Take a chill pill. I do not mean to chide you but your take on people and other things just might be inacurrate. Why don't

[Noteable]

simple fact  .... all those manipulative trader/brokers, the likes of Quentin30, lonc17, O'henry, numbersxnumbers, Lesalpes29, Venture009, CMHarring218431, and crew ... have an agenda here.

[Noteable]

The only thing that adds up is the manipulation happening on this message board, like the views in this and other named posters. Comment by Buckhenryon Feb 05, 2024 12:45pm RE:RE:RE:RE:RE:RE:RE:RE:RE:ONCY January 2024 slide deck - over 120 panc pts studied  0 321

[Buckhenry]

The pumpers can continue their coulda woulda shoulda  and pick words apart on onc  website presentation  but all that really matters in the end is the trend of the stock price. They have absolutely nothing to sink their teeth into. I would love a 10 billion buyout but I will remain realistic in my assessment. 

[Noteable]

No couda, wouda, should with Merck's CEO Robert Davis going on the record saying that the company's acquisition "sweet spot" is US$ 10+  Billion. That's a fact.

[Lesalpes29]

Mental issues ... no no he is only a frustrated man! No I got it ... he is a genius! 

[Noteable]

And again ! ... those manipulative trader/brokers, the likes of Quentin30, lonc17, O'henry, numbersxnumbers, Lesalpes29, Venture009, CMHarring218431, and crew on this and other message boards, through the apparent likes of CIBC World Markets and Canacccord, as examples, have been involved in manipulating the price of this stock at a "full bore" pace, unsuccesffuly trying to acquire a

[13X2413]

Oh oh, I see signs of panic in Noteable. He fought a long losing battle and I think he's about to cave. Reality is sinking in. He can only repeat things unrelated to ONC for so long. Generalities about the BP industry hold no water here.  The share manipulation approach is grasping at straws.  Accept the fact that we got taken by this pump job. 

[Noteable]

Wrong again ! ... however those manipulative trader/brokers, the likes of Quentin30, lonc17, O'henry, numbersxnumbers, Lesalpes29, Venture009, CMHarring218431, and crew on this and other message boards, through the apparent likes of CIBC World Markets and Canacccord, as examples, have been involved in manipulating the price of this stock at a "full bore" pace, unsuccesffuly

[13X2413]

Boring and predictable response. Come up with new stuff. :)

[Quentin30]

are you retarded Noteable..?? I'm just a disgruntled investor who's gotten sick and tired of seeing the the unending just around the corner promises... and the pumper crowd who act as though Matt Coffey walks on water... I still have money tied up in this piece of doggie sh 1t some call a biotech company... If ONCY does go it alone, then ten years of Matt and his rpedessor Brad on record

[Buckhenry]

Unnoteable and cronies beginning to see the reality here but they will never admit it. Going down with the ship but I believe we can stop the water from gushing in. 

[Buckhenry]

Reality allows rears its ugly head at some point. If one keeps a realistic view they are not disappointed and have to resort to discrediting  tactics..  Kinda like politicians do. 

[Noteable]

FDA said that it “may be acceptable” in a confirmatory trial for sponsors to evaluate the drug in the same cancer type but in another line of therapy, such as earlier-stage disease, as ONCY intends to do in L1 pancreatic cancer and potentially in mBC. “This approach has the potential to provide access to effective drugs to patients with earlier-stage disease in which benefit may be greater, and it

[Noteable]

The evolving metastatic pancreatic cancer arm of the Goblet Phase 2 study involving pelareorep + atezolizumsb + n-paclitaxel had the following still maturing findings at the time of the trial cut-off date : an overall response rate (ORR) of 62% (54% confirmed by two or more scans), a Disease Control Rate (DCR) of 85%, 7.2 months of median progression-free survival (mPFS), interim median overall

[Noteable]

According to Pancreatic Cancer UK .."The one year survival for stage 4 pancreatic cancer is 8%. This means 8 out of 100 people will be alive, one year after their diagnosis. Stage 4 cancer is known as advanced or metastatic cancer. This means the cancer has spread outside the pancreas to other parts of the body, and surgery to remove it isn’t possible. Advanced cancer can sometimes

[Noteable]

ONCY's Phase 2 Goblet -1 pancreatic cohort interim results reported at ESMO 2023 in October 2023 showed that pelareorep + atezolizumab + chemotherapy resulted in an interim median overall survival rate of 10.6 months in Stage IV (advanced or metastatic) pancreatic cancer patients which is a significant life survival improvement over findings from an overall study of 625 pancreatic cancer

[Noteable]

Reportedly the one year survival for Stage IV (advanced or metastatic) cancer patients is 8% which would mean that in ONCY's Phase 2 Goblet-1 pancreatic cancer cohort with 13 evaluable patients, only 1.04 patients should have reached the one year survival milestone. However in October 2023 ONCY reported that the 12 month survival rate in the evaluated Stage IV patients was 46%, 

[Noteable]

And this is just one of the many new things that I posted: ... Reportedly the one year survival for Stage IV (advanced or metastatic) cancer patients is 8% which would mean that in ONCY's Phase 2 Goblet-1 pancreatic cancer cohort with 13 evaluable patients, only 1.04 patients should have reached the one year survival milestone. However in October 2023 ONCY reported that the 12 month survival

[Noteable]

Pancreatic Cancer Adaptive Phase 3 (confirmatory trial) intended to begin in mid-2024 - suggests Accelerated Approval and ONCY acquisition by Big Pharma before this timeline.

[Noteable]

The (pancreatic) data from this study show a correlation between the expansion of TIL-specific clones and tumor response, which provides compelling support for the use of pelareorep-based therapies in immunologically "cold" tumors. In particular, these data, along with the impressive clinical results, support the ability of pelareorep-checkpoint inhibitor combination therapies to

[Noteable]

The results of over 120 pancreatic patients in ONCY's Adaptive Pancreatic Cancer studies (REO-17 and Goblet) are enough for an Accelerated Approval, followed by a confirmatory Phase 3 study by mid this year. The Pancreatic Cancer Adaptive Phase 3 (confirmatory trial) intended to begin in mid-2024 - suggests Accelerated Approval and ONCY acquisition by Big Pharma before this timeline.

[Noteable]

February 02, 2024 - The long-acting human interleukin-7, efineptakin alfa (NT-17), has received an orphan drug designation (ODD) from the FDA for use as a potential therapeutic option in patients with pancreatic cancer.  The safety and efficacy of efineptakin alfa paired with pembrolizumab (Keytruda) is under investigation in patients with advanced solid tumors, including pancreatic

[Noteable]

As a general reminder of pelareorep's evolving safety and effectiveness - ONCY's Phase 2 Goblet study PDAC cohort involving pelareorep with atezolizumab resulted in  the following data:  - Objective Response Rate (ORR) of 62% (54% confirmed by two or more scans) - A Disease Control Rate (DCR) of 85%   Survival data: Evaluated based on 4

[Noteable]

Repeating this for the gang of traders/broker manipulators ... Positive Data from over 120 pancreatic cancer patients in the GOBLET and REO-017 open label trials showed meaningful improvements in survival ONCY's adaptive study involving  more than 120 pancreatic patients is more than sufficient when applying for an FDA's Accelerated Approval  Plans are underway

[Noteable]

Here is what ONCY communicated in their January 2024 investor relations slide deck: Positive Data from over 120 pancreatic cancer patients in the GOBLET and REO-017 open label trials showed meaningful improvements in survival [ nterpreted as: ONCY's adaptive study involving more than 120 pancreatic patients is more than sufficient when applying for an FDA's Accelerated

[Noteable]

FDA said that it “may be acceptable” in a confirmatory trial for sponsors to evaluate the drug in the same cancer type but in another line of therapy, such as earlier-stage disease, as ONCY intends to do in L1 pancreatic cancer and potentially in mBC. “This approach has the potential to provide access to effective drugs to patients with earlier-stage disease in which benefit may be greater, and

[Noteable]

An Accelerated Approval will provide more than sufficient $$$ for ONCY to run as many Phase 2 confirmatory clinical trials as their hearts desire. Do you understand Canadafan?

[Noteable]

Should read: ... An Accelerated Approval will provide more than sufficient $$$ for ONCY to run as many Phase 3 confirmatory clinical trials as their hearts desire. Do you understand Canadafan?

[ENEMENEMYNEMO]

Hahah you guys are funny arguing with a B  O  T

[Noteable]

In the event that you also missed this because you were once again caught up in your conspiracy "bot" stuf .... " the evolving metastatic pancreatic cancer arm of the Goblet Phase 2 study involving pelareorep + atezolizumsb + n-paclitaxel had the following still maturing findings at the time of the trial cut-off date : an overall response rate (ORR) of 62% (54% confirmed by two or